Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
58.57
+3.47 (6.30%)
At close: Aug 13, 2025, 4:00 PM
58.00
-0.57 (-0.97%)
After-hours: Aug 13, 2025, 7:44 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $232.09M in the quarter ending June 30, 2025, with 30.95% growth. This brings the company's revenue in the last twelve months to $828.85M, up 28.74% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$828.85M
Revenue Growth
+28.74%
P/S Ratio
8.74
Revenue / Employee
$410,118
Employees
2,021
Market Cap
7.30B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GH News
- 6 days ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 9 days ago - American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity - Business Wire
- 13 days ago - Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 13 days ago - Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Benzinga
- 13 days ago - Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 14 days ago - Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+ - Business Wire
- 15 days ago - New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer - Business Wire